Arbutus Biopharma Corporation (ABUS) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
ABUS's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ABUS Revenue Analysis (2013–2024)
As of February 28, 2026, Arbutus Biopharma Corporation (ABUS) generated trailing twelve-month (TTM) revenue of $14.6 million, reflecting significant decline in growth of -60.5% year-over-year. The most recent quarter (Q3 2025) recorded $529,000 in revenue, down 95.1% sequentially.
Looking at the longer-term picture, ABUS's 5-year compound annual growth rate (CAGR) stands at +0.5%, indicating moderate growth over time. The company achieved its highest annual revenue of $39.0 million in 2022.
Revenue diversification analysis shows ABUS's business is primarily driven by License (53%), and Non-Cash Royalty (47%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), ABUS has underperformed the peer group in terms of revenue growth. Compare ABUS vs ALNY →
Peer Comparison
Compare ABUS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ABUSCurrent | $15M | -60.5% | +0.5% | -1236.7% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $6.2M | -66.0% | $6.2M | 100.0% | $-76,319,000 | -1236.7% |
| 2023 | $18.1M | -53.5% | $18.1M | 100.0% | $-78,103,000 | -430.5% |
| 2022 | $39.0M | +255.1% | $39.0M | 100.0% | $-65,456,000 | -167.8% |
| 2021 | $11.0M | +58.9% | $11.0M | 100.0% | $-73,522,000 | -669.1% |
| 2020 | $6.9M | +15.0% | $-40,567,000 | -586.7% | $-57,806,000 | -836.1% |
| 2019 | $6.0M | +1.9% | $-51,590,000 | -858.3% | $-143,901,000 | -2394.0% |
| 2018 | $5.9M | -44.9% | $-52,000,000 | -881.4% | $-89,800,000 | -1522.0% |
| 2017 | $10.7M | +613.3% | $-52,000,000 | -486.0% | $-110,900,000 | -1036.4% |
| 2016 | $1.5M | -94.0% | $-59,800,000 | -3986.7% | $-491,600,000 | -32773.3% |
| 2015 | $24.9M | +65.8% | $-26,632,000 | -107.1% | $-102,322,000 | -411.4% |
See ABUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ABUS vs AGIO
See how ABUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ABUS's revenue growth accelerating or slowing?
ABUS revenue declined -60.5% year-over-year, contrasting with the 5-year CAGR of +0.5%. TTM revenue fell to $15M. This reverses the prior growth trend.
What is ABUS's long-term revenue growth rate?
Arbutus Biopharma Corporation's 5-year revenue CAGR of +0.5% reflects the variable expansion pattern. Current YoY growth of -60.5% is below this long-term average.
How is ABUS's revenue distributed by segment?
ABUS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.